DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension (Darusentan)

February 19, 2014 updated by: Gilead Sciences

DORADO-EX - A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311-E)

This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan in subjects with resistant systolic hypertension despite treatment with full doses of three or more antihypertensive medications, including a diuretic.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

282

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina
        • CIMEL
      • Buenos Aires, Argentina
        • DIM (Clinica Privada)
      • Buenos Aires, Argentina
        • Fundapres
      • Buenos Aires, Argentina
        • Hospital Británico de Buenos Aires
      • Buenos Aires, Argentina
        • Hospital Jose Maria Ramos Meijia
      • Buenos Aires, Argentina
        • Hospital Municipal bernardo Houssay
      • Buenos Aires, Argentina
        • Medeos
      • Buenos Aires, Argentina
        • Sanatorio Municipal
  • Brazil
      • Sao Paulo, Brazil
        • Centro Integrado Hospital do Rim e Hipertensao
      • Sao Paulo, Brazil
        • Centro integrado hospital
  • Canada
    • Ontario
      • Cambridge, Ontario, Canada, N3H 3R8
        • Cambridge Cardiac Care Center
      • Kitchener, Ontario, Canada, N2G 1G5
        • Clinical Research Solutions
  • Denmark
      • Hvidovre, Denmark
        • Hvidovre Hospital
      • København, Denmark
        • Bispebjerg Hospital
  • France
      • Dommartin les Toul, France
        • CIC Hopital Jeanne D'Arc
      • Grenoble Cedex, France
        • Chu de Grenoble
      • Strasbourg Cedex, France
        • Hôpital Civil, Service HTA maladies vasculaires
  • Sweden
      • Stockholm, Sweden
        • Cardiovascular Research, Karolinska Institue
      • Umea, Sweden
        • University Hospital Umeå
  • United Kingdom
      • Scotland, United Kingdom
        • Townhead Surgery
      • Wiltshire, United Kingdom
        • Avenue Surgery
      • Wiltshire, United Kingdom
        • Hathaway Medical Centre
  • United States
    • Alabama
      • Mobile, Alabama, United States, 36608
        • Comprehensive Heart Failure Center
    • Arizona
      • Tucson, Arizona, United States, 85712
        • Canyon Clinical Research
    • California
      • Inglewood, California, United States, 90301
        • Chrishard Medical Group
      • Los Angeles, California, United States, 90073
        • VA Medical Center - WLA
      • Sacramento, California, United States, 95825
        • Sacramento Heart and Vascular
      • Santa Ana, California, United States, 92705
        • Apex Research Institute
    • Colorado
      • Denver, Colorado, United States, 80220
        • Complete Renal Care
    • Connecticut
      • Bridgeport, Connecticut, United States, 06606
        • Connecticut Clinical Research, Llc
    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • MedStar Diabetes Institute at Washington Hospital Center
    • Florida
      • Fort Walton Beach, Florida, United States, 32569
        • White-Wilson Medical Center
      • Hialeah, Florida, United States, 33012
        • A.G.A. Clinical Trials
      • Jacksonville, Florida, United States, 32216
        • Jacksonville Center for Clinical
      • Jupiter, Florida, United States, 33458
        • Ricardo A. Bedoya, Cardiology
      • Miami, Florida, United States, 33156
        • International Research Association
      • Sarasota, Florida, United States, 34231
        • Cardiovascular Center of Sarasota
      • Tampa, Florida, United States, 33603
        • Tampa Bay Nephrology Associates, PL
      • West Palm Beach, Florida, United States, 33401
        • Metabolic Research Institute, Inc.
    • Georgia
      • Calhoun, Georgia, United States, 30701
        • Global Research Partners
    • Hawaii
      • Honolulu, Hawaii, United States, 96816
        • Kula Research
    • Illinois
      • Elk Grove Village, Illinois, United States, 60007
        • Chicago Heart & Vein Clinic
      • Evanston, Illinois, United States, 60201
        • Evanston Northwestern Healthcare
      • Gurnee, Illinois, United States, 60031
        • Clinical Investigation Specialists, Inc.
      • Lombard, Illinois, United States, 60148
        • Midwest Heart Foundation
    • Louisiana
      • Slidell, Louisiana, United States, 70458
        • Medical Research Institute
    • Maine
      • Auburn, Maine, United States, 04210
        • Maine Research Associate
      • Auburn, Maine, United States, 04210
        • Androscoggin Cardiology Associates
      • Scarborough, Maine, United States, 04074
        • Cardiovascular Consultants of Maine
    • Maryland
      • Reisterstown, Maryland, United States, 21136
        • Clinical Associates
      • Rockville, Maryland, United States, 20854
        • Rockville Internal Medicine Group
    • Michigan
      • Benzonia, Michigan, United States, 49616
        • Professional Clinical Research
      • Flint, Michigan, United States, 48503
        • Hurley Medical Center
      • Interlochen, Michigan, United States, 49643
        • Professional Clinical Research
    • Nevada
      • Pahrump, Nevada, United States, 89048
        • Specialty Medical Center
    • North Carolina
      • Greenville, North Carolina, United States, 27834
        • Physicians East, PA
    • Ohio
      • Cincinnati, Ohio, United States, 45219
        • The Lindner Clinical Trial Center
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73003
        • COR Clinical Research
      • Oklahoma City, Oklahoma, United States, 73109
        • Southwest Cardiology Associates
      • Tulsa, Oklahoma, United States, 74136
        • Castlerock Clinical Research Consultants
    • Oregon
      • Hillsboro, Oregon, United States, 97123
        • Hillsboro Cardiology, PC
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
        • Northeast Clinical Research Centers, Inc.
      • Camp Hill, Pennsylvania, United States, 17011
        • Heritage Cardiology Associates
      • Downingtown, Pennsylvania, United States, 19335
        • Brandywine Clinical Research
      • Lansdale, Pennsylvania, United States, 19446
        • Green and Seidner Family Practice Associates
      • Philadelphia, Pennsylvania, United States, 19140
        • Temple University Hospital
    • Rhode Island
      • Providence, Rhode Island, United States, 02903
        • RI Hospital
    • South Carolina
      • Columbia, South Carolina, United States, 29201
        • Neem Research Group, Inc.
    • Texas
      • Desoto, Texas, United States, 75115
        • Internal Medicine & Industrial Medicine
      • Ft Worth, Texas, United States, 76117
        • T&R Clinical, P.A.
      • Lewisville, Texas, United States, 75067
        • Pri-Med Care
      • San Antonio, Texas, United States, 78229
        • Innovative Clinical Trials
    • Virginia
      • Burke, Virginia, United States, 22015
        • Burke Internal Medicine, Inc.
      • Manassas, Virginia, United States, 20110
        • Manassas Clinical Research Center
    • Washington
      • Tacoma, Washington, United States, 98405
        • Liberty Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subjects who have completed the Treatment Period of clinical trial DAR-311
  • Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic

Exclusion Criteria:

  • Subjects who discontinued treatment with study drug prior to the end of the Treatment Period of DAR-311 due to a study drug-related adverse event (AE)
  • Treatment with another endothelin receptor antagonist within 6 months of study entry

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Darusentan 50 mg
Darusentan 50 mg administered orally once daily
Drug: Darusentan
Darusentan capsules administered orally once daily
EXPERIMENTAL: Darusentan 100 mg
Darusentan 100 mg administered orally once daily
Drug: Darusentan
Darusentan capsules administered orally once daily
EXPERIMENTAL: Darusentan 300 mg
Darusentan 300 mg administered orally once daily
Drug: Darusentan
Darusentan capsules administered orally once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in trough sitting systolic and diastolic blood pressure
Time Frame: Baseline to Week 14
Baseline to Week 14

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in mean 24-hour systolic and diastolic ambulatory blood pressures.
Time Frame: Baseline to Week 14
Baseline to Week 14
Percentage of subjects who reach systolic blood pressure goal
Time Frame: Week 14
Week 14
Change in estimated glomerular filtration rate (eGFR)
Time Frame: Baseline to Week 14
Baseline to Week 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gilead Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2006

Primary Completion (ACTUAL)

February 1, 2010

Study Completion (ACTUAL)

April 1, 2010

Study Registration Dates

First Submitted

July 17, 2006

First Submitted That Met QC Criteria

July 17, 2006

First Posted (ESTIMATE)

July 18, 2006

Study Record Updates

Last Update Posted (ESTIMATE)

March 18, 2014

Last Update Submitted That Met QC Criteria

February 19, 2014

Last Verified

February 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DAR-311-E

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Darusentan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe